Stay updated with breaking news from Coyote Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Mexican scientists introduced 'Pablo,' an AI application enabling real-time epidemiological surveillance, poised to revolutionize diagnostics and resource allocation in virus outbreak management.
Share this article Share this article JUPITER, Fla., Feb. 1, 2021 /PRNewswire/ -- Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, announced today that it has added two life science industry veterans to its senior management team. Roger Schaller has been appointed Executive Vice President (EVP) of Commercial Operations, and Amy Chandler has been promoted to Executive Vice President (EVP) for Regulatory Affairs and Quality Man...
GL Ventures leads $92m Series D in Chinese molecular diagnostics specialist Coyote Coyote Bioscience. Visuals from the company website Premium GL Ventures, the venture capital (VC) arm of Hillhouse Capital, has led a Series D funding of nearly 600 million yuan ($91.6 million) in Coyote Bioscience, a Chinese molecular diagnostics firm that specialises in point-of-care testing (POCT). Continue reading this story with a subscription to DealStreetAsia. Contact us for corporate subscriptions at subs@dealstreetasia.com. Sign up for our newsletter - The Daily Brie...